Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach
Condition(s):Pancreatic Ductal AdenocarcinomaLast Updated:November 30, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Pancreatic Ductal AdenocarcinomaLast Updated:November 30, 2023Not yet recruiting
Condition(s):Pancreatic Ductal AdenocarcinomaLast Updated:March 12, 2024Active, not recruiting
Condition(s):Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma; Pancreatic DysplasiaLast Updated:March 6, 2024Not yet recruiting
Condition(s):Metastatic Pancreatic Ductal AdenocarcinomaLast Updated:August 21, 2023Recruiting
Condition(s):Pancreatic Adenocarcinoma; Pancreatic Intraepithelial NeoplasiaLast Updated:March 6, 2024Enrolling by invitation
Condition(s):PDAC – Pancreatic Ductal AdenocarcinomaLast Updated:May 3, 2023Recruiting
Condition(s):Pancreatic Ductal AdenocarcinomaLast Updated:March 12, 2024Enrolling by invitation
Condition(s):Pancreatic Ductal AdenocarcinomaLast Updated:March 24, 2023Recruiting
Condition(s):Pancreatic Ductal Adenocarcinoma; Pancreatic CancerLast Updated:February 8, 2024Recruiting
Condition(s):Pancreatic Ductal Adenocarcinoma; Refractory Non-Small Cell Lung CancerLast Updated:February 5, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.